- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02630901
Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Subjects With Psoriasis
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- TCR Medical Corporation
-
-
Florida
-
Coral Gables, Florida, United States
- Universal Medical and Research Center, LLC
-
Ocala, Florida, United States, 34471
- Renstar Medical Research
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Case Medical Center
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Altoona Center for Clinical Research
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC Department of Dermatology
-
-
Texas
-
Dallas, Texas, United States
- Dermatology Treatment and Research Center, PA
-
San Antonio, Texas, United States
- Clinical Trials of Texas, Inc.
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Virginia Clinical Research Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, 18 to 80 years of age (inclusive), body weight range of ≥ 45 kg (99 lbs) to ≤ 120 kg (264 lbs) and a body mass index (BMI) of 18 - 35 kg/m2
- Provide written informed consent
- PASI score of ≥12
- Plaque psoriasis covering ≥10% of BSA
- s-PGA score of 3 or 4
- Able to perform all protocol-specified assessments and comply with the study visit schedule
- Female subjects who are not postmenopausal or surgically sterile must use physician approved contraception for at least 60 days prior to Baseline (Day 1/Visit 2) to 12 weeks following the last study drug administration. Unless they are at least 2 years postmenopausal or surgically sterile, women must have a pregnancy test with follicle stimulating hormone (FSH) >40 IU/L and estradiol <20 pg/mL (unless on hormone-replacement therapy). Women of childbearing potential must be non lactating and have a negative serum pregnancy test (beta human chorionic gonadotropin [β HCG]) at Screening (Visit 1).
- If male, must be surgically sterile or must agree to use physician-approved contraception from Baseline (Day 1/Visit 2) to 12 weeks following the last study drug administration
Exclusion Criteria:
- Presents with psoriasis that is predominantly guttate, erythrodermic, inverse, pustular or palmo-plantar, or an unstable form of psoriasis
Receipt of any of the following within the specified time frame prior to Baseline (Day 1/Visit 2):
- Topical psoriasis treatments (other than low-potency topical corticosteroids or emollients, which are permitted during the study) within 2 weeks
- Systemic (nonbiologic) psoriasis treatments within 4 weeks or 5 half-lives (whichever is longer)
- Biologic psoriasis treatments within 12 weeks or 5 half-lives (whichever is longer)
- Drugs that appear to have a strong causal relationship to psoriasis (e.g., beta-blockers and lithium) within 4 weeks or 5 half-lives (whichever is longer)
- Phototherapy within 4 weeks
- Participation in recreational sunbathing or use of a sun-bed (e.g., tanning salon) within 7 days prior to Baseline (Day 1)
Any major medical illness or unstable medical condition that, in the opinion of the Investigator or Sponsor, may interfere with the subject's ability to comply with study procedures or abide by study restrictions, or with the ability to interpret safety data, including, but not limited to:
- Within 5 years of Screening (Visit 1)
- History of cancer with the exception of fully excised non-melanoma skin cancer
- History of stroke
- History of epilepsy or seizure disorder other than febrile seizures as a child, or any seizure or loss of consciousness
- History of or active autoimmune disease (other than psoriasis or PsA)
- Within 2 years of Screening (Visit 1)
- Myocardial infarction
- Clinically significant cardiovascular disease including any of the following: unstable angina, decompensated congestive heart failure, clinically significant arrhythmias
- Vascular diseases, including, but not limited to, blood clotting disorders, atherosclerosis, aneurysms, and renal artery disease
- Hypotension (systolic blood pressure [BP] ≤85 millimeters of mercury [mmHg]) at Baseline (Day 1/Visit 2) predose or a known history or documentation of hypotension on more than one occasion within 3 months prior to Baseline (Day 1/Visit 2)
- Uncontrolled hypertension as indicated by a resting systolic BP ≥150 mmHg or diastolic BP ≥95 mmHg at Screening (Visit 1) or Baseline (Day 1/Visit 2) predose or a known history or documentation of uncontrolled hypertension on more than one occasion within 3 months prior to Baseline (Day 1/Visit 2)
- Clinically significant systemic infection (e.g., chronic or acute infection, urinary tract infection, upper respiratory infection) within 30 days of Baseline (Day 1/ Visit 2), or a history or presence of recurrent or chronic infection (e.g., viral infections [including hepatitis B or C, human immunodeficiency virus (HIV)], bacterial infections, systemic fungal infections, or syphilis)
- History of any inflammatory bowel disease
- Any current psychiatric diagnosis according to Diagnostic and Statistical Manual of Mental Disorders IV Text Revision (DSM-IV-TR) that may interfere with the subject's ability to perform the study and all assessments (e.g., alcohol or drug-related abuse or alcohol dependence, or alcohol or drug-related dementia, major depression, developmental disability, schizophrenia, bipolar disorder). Note: Subjects with adequately controlled depression for at least 6 months are not excluded; however, suicidal ideation or attempt at any time within the past year is exclusionary.
A positive tuberculosis skin test (TST) or a positive interferon-gamma release assay (IGRA) during Screening (Visit 1).
Note: In the event a subject has had a TST or IGRA within 3 months before Baseline (Day 1/Visit 2), this does not need to be repeated during screening and the previous result can be carried forward and used in this study.
Prior standard treatment for latent tuberculosis and prior exposure to tuberculosis with subsequent standard prophylactic treatment is allowed if recent (within ˂ 30 days) negative chest X-ray.
Any of the following laboratory abnormalities at Screening (Visit 1):
- Total bilirubin (unless attributed to Gilbert's syndrome) >1.5 times the upper limit of normal (× ULN), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 × ULN
- Serum creatinine >133 µmol/L (1.5 mg/dL)
- Hemoglobin <11.5 g/dL for males or <10.0 g/dL for females, absolute neutrophil count of ˂1500/µL (with the exception of a documented history of a chronic benign neutropenia), or platelet count of <120,000/µL
- Use of an investigational product or device or participation in a drug research study within a period of 30 days (or 5 half-lives of the drug, whichever is longer) prior to Screening (Visit 1); for investigational products or drug research studies relating to psoriasis or arthritis, the duration will be extended to 12 weeks (or 5 half-lives of the drug, whichever is longer) prior to Screening (Visit 1)
- Allergy to any of the components of PRX003 such as histidine, sucrose and polysorbate 20
- Receipt of any vaccine (with the exception of seasonal influenza) within 30 days prior to Screening (Visit 1)
- Donation of >500 mL of blood within 3 months prior to Screening (Visit 1)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: PRX003
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability as determined by number of subjects with adverse events
Time Frame: 6 months
|
6 months
|
|
Determination of pharmacokinetics parameters
Time Frame: 20 weeks
|
time of the maximum measured concentration (Tmax)
|
20 weeks
|
Determination of pharmacokinetics parameters
Time Frame: 20 weeks
|
area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast)
|
20 weeks
|
Determination of pharmacokinetics parameters
Time Frame: 20 weeks
|
maximum concentration (Cmax)
|
20 weeks
|
Determination of pharmacokinetics parameters
Time Frame: 20 weeks
|
area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)
|
20 weeks
|
Determination of pharmacokinetics parameters
Time Frame: 20 weeks
|
elimination rate constant
|
20 weeks
|
Determination of pharmacokinetics parameters
Time Frame: 20 weeks
|
terminal elimination half life (t½)
|
20 weeks
|
Determination of pharmacokinetics parameters
Time Frame: 20 weeks
|
clearance (CL)
|
20 weeks
|
Determination of pharmacokinetics parameters
Time Frame: 20 weeks
|
apparent volume of distribution (Vd)
|
20 weeks
|
Determination of pharmacokinetics parameters
Time Frame: 20 weeks
|
average concentration over a dosing interval (Cav)
|
20 weeks
|
Determination of pharmacokinetics parameters
Time Frame: 20 weeks
|
area under the plasma concentration-time curve for a dosing interval (AUCtau)
|
20 weeks
|
Determination of pharmacokinetics parameters
Time Frame: 20 weeks
|
minimum observed concentration (Cmin)
|
20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity as determined by measurement of anti-PRX003 antibodies
Time Frame: 20 weeks
|
antibody titers will be listed and summarized
|
20 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRX003-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States